Head-to-Head Poll: Prime Medicine (NYSE:PRME) Vs. CERo Therapeutics (NASDAQ:CERO)

CERo Therapeutics ( NASDAQ:CERO – Get Free Report ) and Prime Medicine ( NYSE:PRME – Get Free Report ) are both small-cap medical companies, but which is the better stock? We’ll compare the two companies based on risk strength, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Institutional and insider ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 15.8% of CERo Therapeutics shares are held by insiders. Comparatively, 24.3% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, big money managers and endowments believe a company is poised for long-term growth.

Analyst ratings

This is a summary of current ratings for CERo Therapeutics and Prime Medicine, as reported by MarketBeat.

Prime Medicine has a consensus target price of $15.09, indicating a potential upside of 259.74%. Given Prime Medicine’s higher possible upside, analysts plainly believe Prime Medicine is more favorable than CERo Therapeutics.

Earnings and Rating

This table compares CERo Therapeutics and Prime Medicine’s top-line revenue, earnings per share and valuation.

CERo Therapeutics has higher earnings, but lower revenue than Prime Medicine.

return

This table compares CERo Therapeutics and Prime Medicine’s net margins, return on equity and return on assets.

Risk and volatility

CERo Therapeutics has a beta of -0.46, meaning its share price is 146% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.21, meaning its share price is 121% more volatile than the S&P 500.

Summary

Prime Medicine beats CERo Therapeutics in 6 of the 9 factors compared between the two stocks.

About CERo Therapeutics

(Get a free report)

CERo Therapeutics Holdings, Inc., an immunotherapy company, is focused on advancing the development of engineered T-cell therapy for the treatment of cancer. Its lead program in hematologic malignancies targets an upregulated Eat Me signal on B cells and myeloid tumors. The company is headquartered in South San Francisco, California.

About Prime Medicine

(Get a free report)

Prime Medicine, Inc., a biotechnology company, provides gene therapies to address the spectrum of diseases by implementing gene editing technology. The company offers Prime Editors with a Prime Editor protein, which comprises a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template to make the desired editing of the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop protected cell pairs and edited immunotherapy for genetic diseases, acute myeloid leukemia and myelodysplastic syndrome. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Get news and reviews for CERo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CERo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.